论文部分内容阅读
目的探讨重组人干扰素α1b与利巴韦林雾化吸入治疗小儿毛细支气管炎的疗效。方法将福建省妇幼保健院2014年5月至2016年5月收治的152例小儿毛细支气管炎患儿随机分为3组,在给予布地奈德、异丙脱溴胺雾化的基础上,分别加用利巴韦林(0.1g/次)、重组人干扰素低剂量(2μg/kg·次)和高剂量(4μg/kg·次,均2次/d)。比较3组疗效及不良反应。结果重组人干扰素低剂量组(54例)、高剂量组(47例)和利巴韦林组(51例)治疗总有效率分别为92.6%和93.6%和78.4%,重组人干扰素低、高剂量组咳嗽、喘息和三凹征、肺部喘鸣音等症状体征消失时间比利巴韦林组缩短,不良反应少;利巴韦林组有皮疹、腹泻、粒细胞减少等不良反应。结论重组人干扰素α1b雾化吸入治疗小儿毛细支气管炎的疗效比利巴韦林好,无明显不良反应;其低剂量与高剂量疗效相似。
Objective To investigate the efficacy of recombinant human interferon α1b and ribavirin aerosol inhalation in the treatment of children with bronchiolitis. Methods 152 children with bronchiolitis from May 2014 to May 2016 in Fujian Province were randomly divided into three groups. On the basis of budesonide and isodebromide atomization, Addition of ribavirin (0.1g / time), recombinant human interferon low dose (2μg / kg · times) and high dose (4μg / kg times, both 2 times / d). The efficacy and adverse reactions of three groups were compared. Results The total effective rate was 92.6%, 93.6% and 78.4% in the low dose interferon group (54 cases), high dose group (47 cases) and ribavirin group (51 cases), respectively. The total effective rate of recombinant human interferon , The cough, wheezing and trilhalus sign in the high-dose group, the lungs wheeze and other symptoms disappeared in a shorter time than the ribavirin group, with fewer side effects; the ribavirin group had adverse reactions such as rash, diarrhea and neutropenia . Conclusion The therapeutic effect of inhalation of recombinant human interferon α1b on children with bronchiolitis is better than that of ribavirin, and there is no obvious adverse reaction. The efficacy of low-dose and high-dose is similar.